Tyra Biosciences Inc: 5%+ holders

As of November 6, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Tyra Biosciences Inc. The largest reported stake is RA Capital Management, L.P.'s, at 19.9%. 21 filings are on record since August 14, 2025 (Schedule 13D/A, September 17, 2026).

Canaan XI L.P. also filed stake reports on 1 other company ↓

Sell to companies like Tyra Biosciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-27 · Reporting person: BlackRock, Inc. · Sole voting: 3,243,666 · Shared voting: 0 · Sole dispositive: 3,304,658 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
• Filing 2026-09-21 · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 2,203,710 · Sole dispositive: 0 · Shared dispositive: 2,203,710 · SCHEDULE 13G, 2026-09-21
• Filing 2026-09-17 · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 14,130,492 · Sole dispositive: 0 · Shared dispositive: 14,130,492 · SCHEDULE 13D/A, 2026-09-17
• Filing 2026-09-17 · Reporting person: Paradigm BioCapital Advisors LP · Sole voting: 3,473,453 · Shared voting: 0 · Sole dispositive: 3,473,453 · Shared dispositive: 0 · SCHEDULE 13G, 2026-09-17
• Filing 2026-08-14 · Reporting person: Nextech VI Oncology SCSp · Sole voting: 3,553,585 · Shared voting: 0 · Sole dispositive: 3,553,585 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14

Tyra Biosciences Inc has 21 Schedule 13D or 13G filings on record since 2025-08-14. 7 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Tyra Biosciences Inc and the warning signs.

See Tyra Biosciences Inc's free Snapshot Watch Tyra Biosciences Inc: email me the next time it files something

Free to see. No signup.

Keep reading

More on Tyra Biosciences Inc and the records around it.

Tyra Biosciences Inc elsewhere on the record

• Leadership changes Apr 2026
• Who owns it

Companies that share a holder

• Canaan XI L.P. also filed stake reports on 1 other company: AEVA TECHNOLOGIES, INC. (Jul 2025)
• Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
• Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)

Want the whole picture on Tyra Biosciences Inc?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Tyra Biosciences Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Tyra Biosciences Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   23 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Tyra Biosciences Inc by CUSIP 90240B106 and gives its principal executive office as 2656 State Street, Carlsbad, CA 92008 (SCHEDULE 13G/A, 2026-10-27).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.Nextech VI Oncology SCSp, SCHEDULE 13G/A, 2026-08-14

See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 59,676,939 shares of Common Stock outstanding as of July 31, 2026, as reported by the Issuer in its Form 10-Q filed with the SEC on August 4, 2026.Paradigm BioCapital Advisors LP, SCHEDULE 13G, 2026-09-17

Source of funds (Item 3)

Item 3 of the Statement is hereby amended and supplemented as follows: On September 15, 2026, the Fund purchased Pre-Funded Warrants exercisable for up to 9,078,529 shares of common stock at a price of $22.029 per Pre-Funded Warrant, from the underwriters of the Issuer's public offering (the "September 2026 Offering"). The aggregate purchase price for the Pre-Funded Warrants acquired by the Fund in the September 2026 Offering was $199,990,915.34, which was funded by the working capital of the Fund.RA Capital Management, L.P., SCHEDULE 13D/A, 2026-09-17

Timeline

Swipe the table sideways to see every column.

Questions about who owns Tyra Biosciences Inc

Who owns Tyra Biosciences Inc?

On this page, 7 holders' latest ownership filings report 5% or more of Tyra Biosciences Inc: RA Capital Management, L.P. (19.9%, Schedule 13D/A, filed 2026-09-17), Fmr LLC (14.4%, Schedule 13G, filed 2026-04-07), Janus Henderson Group Plc (7.2%, Schedule 13G/A, filed 2026-05-15), Dapice Joshua J. (6.6%, Schedule 13G/A, filed 2026-05-12) and Bvf Partners L P (6.1%, Schedule 13G, filed 2026-09-21); 2 more are listed above.

Who are the largest shareholders of Tyra Biosciences Inc?

By the share each holder's latest filing reports, the largest holders of Tyra Biosciences Inc on this page are RA Capital Management, L.P. (19.9%), Fmr LLC (14.4%) and Janus Henderson Group Plc (7.2%).

When did RA Capital Management, L.P. buy into Tyra Biosciences Inc?

The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13D/A, filed 2026-03-06, reporting 21.2%; its latest, Schedule 13D/A filed 2026-09-17, reports 19.9%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 21 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Tyra Biosciences Inc

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Tyra Biosciences Inc. With no account yet, you sign up free and land on the result.

• Get an alert when Tyra Biosciences Inc is mentioned again
• Find former Tyra Biosciences Inc employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes